Posterior Reversible Encephalopathy Syndrome and Takotsubo Cardiomyopathy Associated with Lenvatinib Therapy for Thyroid Cancer: a Case Report and Review

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Jul 3

PMID 29963277

Citations 7

Authors

Young Kwang Chae

Lauren Chiec

Scott K Adney

Josh Waitzman

Ricardo Costa

Benedito Carneiro

Maria Matsangou

Mark Agulnik

Peter Kopp

Frank Giles

Affiliations

Soon will be listed here.

Abstract

As immunotherapies including tyrosine kinase inhibitors become more widely used for the treatment of a variety of malignancies, it is important for prescribers and patients to understand the potential adverse effects associated with these drugs. It is especially important to understand the potentially fatal side effects associated with these drugs to further determine risk factors for their development. The review presents a case of posterior reversible encephalopathy syndrome with concomitant Takotsubo cardiomyopathy, associated with use of lenvatinib therapy for thyroid cancer. It discusses the interventions performed and outcome. Potential mechanisms for development of these rare adverse effects, as well as cases in which these adverse effects are seen with use of other tyrosine-kinase inhibitors will be presented. It is important to continue to report these side effects, and further studies are needed to elucidate potential risk factors for their development, as well as to determine prognosis after development.

Citing Articles

Acute vascular and cardiac effects of lenvatinib in mice.

Kruger D, Pannucci P, Wesley C, Neutel C, Martinet W, De Meyer G Cardiooncology. 2025; 11(1):14.

PMID: 39934897 PMC: 11816767. DOI: 10.1186/s40959-025-00307-8.

Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report.

Buenaventura D, Vargas-Sierra H, Aristizabal-Henao N, Torres-Grajales J, Aguilar-Londono C, Gutierrez-Restrepo J Int J Endocrinol Metab. 2023; 21(3):e136900.

PMID: 38028246 PMC: 10676670. DOI: 10.5812/ijem-136900.

Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma.

Tseng Y, Chen C, Hong R, Kung W, Huang A Brain Sci. 2023; 13(1).

PMID: 36672016 PMC: 9856907. DOI: 10.3390/brainsci13010033.

Metastatic medullary thyroid carcinoma: a new way forward.

Angelousi A, Hayes A, Chatzellis E, Kaltsas G, Grossman A Endocr Relat Cancer. 2022; 29(7):R85-R103.

PMID: 35521769 PMC: 9175549. DOI: 10.1530/ERC-21-0368.

Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects.

Hamidi S, Boucher A, Lemieux B, Rondeau G, Leboeuf R, Ste-Marie L J Endocr Soc. 2022; 6(6):bvac048.

PMID: 35475024 PMC: 9032633. DOI: 10.1210/jendso/bvac048.

References

Campbell N, Kunnavakkam R, Leighl N, Vincent M, Gandara D, Koczywas M . Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012; 78(1):76-80. PMC: 4319647. DOI: 10.1016/j.lungcan.2012.06.011. View

Oulad Hadj J, Braven R, Tillier C, Schrijver H, Verheul H, van der Vliet H . Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma. Oncol Lett. 2012; 3(6):1293-1296. PMC: 3392579. DOI: 10.3892/ol.2012.646. View

Chorianopoulos E, Jager D, Katus H, Frey N . Severe cardiomyopathy in a patient with renal cell carcinoma after treatment with the novel tyrosine kinase inhibitor sunitinib. Clin Res Cardiol. 2007; 96(11):829-30. DOI: 10.1007/s00392-007-0567-z. View

Dogan E, Aksoy S, Arslan C, Dede D, Altundag K . Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol. 2009; 27(4):1436-7. DOI: 10.1007/s12032-009-9378-6. View

Fugate J, Claassen D, Cloft H, Kallmes D, Kozak O, Rabinstein A . Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010; 85(5):427-32. PMC: 2861971. DOI: 10.4065/mcp.2009.0590. View

Chelis L, Souftas V, Amarantidis K, Xenidis N, Chamalidou E, Dimopoulos P . Reversible posterior leukoencephalopathy syndrome induced by pazopanib. BMC Cancer. 2012; 12:489. PMC: 3487903. DOI: 10.1186/1471-2407-12-489. View

White A, LaGerche A, Toner G, Whitbourn R . Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist. Int J Cardiol. 2007; 131(3):e92-4. DOI: 10.1016/j.ijcard.2007.07.066. View

Chu T, Rupnick M, Kerkela R, Dallabrida S, Zurakowski D, Nguyen L . Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007; 370(9604):2011-9. PMC: 2643085. DOI: 10.1016/S0140-6736(07)61865-0. View

Costa R, Costa R, Costa R, Junior G, Cartaxo H, de Barros A . Reversible posterior encephalopathy syndrome secondary to sunitinib. Case Rep Oncol Med. 2014; 2014:952624. PMC: 4037124. DOI: 10.1155/2014/952624. View

10.

Foerster R, Welzel T, Debus J, Gruellich C, Jaeger D, Potthoff K . Posterior reversible leukoencephalopathy syndrome associated with pazopanib. Case Rep Oncol. 2013; 6(1):204-8. PMC: 3636956. DOI: 10.1159/000350742. View

11.

Schlumberger M, Tahara M, Wirth L, Robinson B, Brose M, Elisei R . Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372(7):621-30. DOI: 10.1056/NEJMoa1406470. View

12.

Covarrubias D, Luetmer P, Campeau N . Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002; 23(6):1038-48. PMC: 7976914. View

13.

Jang S, Zheng C, Tsai H, Fu A, Barac A, Atkins M . Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. Cancer. 2015; 122(1):124-30. PMC: 4602387. DOI: 10.1002/cncr.29728. View

14.

Padhy B, Shanmugam S, Gupta Y, Goyal A . Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Br J Clin Pharmacol. 2011; 71(5):777-9. PMC: 3093083. DOI: 10.1111/j.1365-2125.2010.03893.x. View

15.

Granata G, Greco A, Iannella G, Granata M, Manno A, Savastano E . Posterior reversible encephalopathy syndrome--Insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2015; 14(9):830-6. DOI: 10.1016/j.autrev.2015.05.006. View

16.

Martin G, Bellido L, Cruz J . Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007; 25(23):3559. DOI: 10.1200/JCO.2007.12.8710. View

17.

Furubayashi N, Negishi T, Iwai H, Nagase K, Nakamura M . Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: A report of two cases. Mol Clin Oncol. 2017; 7(2):281-284. PMC: 5532681. DOI: 10.3892/mco.2017.1291. View

18.

Hobson E, Craven I, Blank S . Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int. 2012; 32(6):590-4. PMC: 3524908. DOI: 10.3747/pdi.2012.00152. View

19.

Govindarajan R, Adusumilli J, Baxter D, El-Khoueiry A, Harik S . Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006; 24(28):e48. DOI: 10.1200/JCO.2006.08.4608. View

20.

Cheng H, Kari G, Dicker A, Rodeck U, Koch W, Force T . A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res. 2011; 109(12):1401-9. PMC: 3908774. DOI: 10.1161/CIRCRESAHA.111.255695. View